HighTower Advisors LLC Decreases Position in Zimmer Biomet Holdings, Inc. $ZBH

HighTower Advisors LLC lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 48.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 17,850 shares of the medical equipment provider’s stock after selling 17,108 shares during the quarter. HighTower Advisors LLC’s holdings in Zimmer Biomet were worth $1,605,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Key Financial Inc lifted its holdings in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $32,000. Grove Bank & Trust lifted its holdings in shares of Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $37,000. Finally, JFS Wealth Advisors LLC lifted its holdings in shares of Zimmer Biomet by 306.7% during the 3rd quarter. JFS Wealth Advisors LLC now owns 427 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Stifel Nicolaus decreased their price objective on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Barclays decreased their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a report on Wednesday, April 29th. Citigroup decreased their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. Wells Fargo & Company decreased their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, April 29th. Finally, UBS Group reissued a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Price Performance

NYSE ZBH opened at $83.70 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The stock’s fifty day moving average price is $87.82 and its 200 day moving average price is $90.61. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a market cap of $16.19 billion, a price-to-earnings ratio of 21.74, a PEG ratio of 1.92 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the prior year, the firm earned $1.81 EPS. The firm’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.